Physician profile
Michael Ham
NPI 1962421081
$785.08
in general payments reported to CMS, 2019-2025
9 companies · $33.86 in 2025
The $33.86 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2021: $44.73 · 2022: $275 · 2023: $185 · 2024: $63.29 · 2025: $33.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244 · Education: $38.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.19 |
| Education | $38.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $259.97 | 2021-2023 | Farxiga |
| Fresenius USA Marketing, INC. | $191.51 | 2019-2025 | Velphoro, Liberty Select Cycler, Nxstage System One |
| Novo Nordisk INC | $129.28 | 2022 | |
| Horizon Therapeutics Plc | $89.98 | 2019 | |
| Travere Therapeutics, INC. | $29.57 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $26.65 | 2022-2023 | Tarpeyo |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Abbott Laboratories | $18.84 | 2022 | |
| Vifor Pharma, INC. | $14.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.